Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

William J. Marks, Jill L. Ostrem, Leonard Verhagen, Philip A. Starr, Paul S. Larson, Roy AE Bakay, Robin Taylor, Deborah Cahn-Weiner, A. Jon Stoessl, C. Warren Olanow, Raymond T. Bartus

Research output: Contribution to journalArticle

398 Citations (Scopus)

Abstract

Background: There is an urgent need for therapies that slow or reverse the progression of Parkinson's disease (PD). Neurotrophic factors can improve the function of degenerating neurons and protect against further neurodegeneration, and gene transfer might be a means to deliver effectively these factors to the brain. The aim of this study was to assess the safety, tolerability, and potential efficacy of gene delivery of the neurotrophic factor neurturin. Methods: In this phase I, open-label clinical trial, 12 patients aged 35-75 years with a diagnosis of PD for at least 5 years in accordance with the UK Brain Bank Criteria received bilateral, stereotactic, intraputaminal injections of adeno-associated virus serotype 2-neurturin (CERE-120). The first six patients received doses of 1·3×1011 vector genomes (vg)/patient, and the next six patients received 5·4×1011 vg/patient. This trial is registered with ClinicalTrials.gov, number NCT00252850. Findings: The procedure was well tolerated. Extensive safety monitoring in all patients revealed no clinically significant adverse events at 1 year. Several secondary measures of motor function showed improvement at 1 year; for example, a mean improvement in the off-medication motor subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) of 14 points (SD 8; p=0.000121 [36% mean increase; p=0.000123]) and a mean increase of 2·3 h (2; 25% group mean increase; p=0·0250) in on time without troublesome dyskinesia were seen. Improvements in several secondary measures were not significant, including the timed walking test in the off condition (p=0·053), the Purdue pegboard test of hand dexterity (p=0·318), the reduction in off time (p=0·105), and the activities of daily living subscore (part II) of the UPDRS (p=0·080). 18F-levodopa-uptake PET did not change after treatment with either dose of CERE-120. Interpretation: The initial data support the safety, tolerability, and potential efficacy of CERE-120 as a possible treatment for PD; however, these results must be viewed as preliminary until data from blinded, controlled clinical trials are available. Funding: Ceregene; Michael J Fox Foundation for Parkinson's Research.

Original languageEnglish (US)
Pages (from-to)400-408
Number of pages9
JournalThe Lancet Neurology
Volume7
Issue number5
DOIs
StatePublished - May 1 2008
Externally publishedYes

Fingerprint

Neurturin
Dependovirus
Parkinson Disease
Safety
Nerve Growth Factors
Genome
Controlled Clinical Trials
Dyskinesias
Brain
Levodopa
Activities of Daily Living
Genes
Walking
Serogroup
CERE
Therapeutics
Hand
Clinical Trials
Neurons
Injections

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease : an open-label, phase I trial. / Marks, William J.; Ostrem, Jill L.; Verhagen, Leonard; Starr, Philip A.; Larson, Paul S.; Bakay, Roy AE; Taylor, Robin; Cahn-Weiner, Deborah; Stoessl, A. Jon; Olanow, C. Warren; Bartus, Raymond T.

In: The Lancet Neurology, Vol. 7, No. 5, 01.05.2008, p. 400-408.

Research output: Contribution to journalArticle

Marks, William J. ; Ostrem, Jill L. ; Verhagen, Leonard ; Starr, Philip A. ; Larson, Paul S. ; Bakay, Roy AE ; Taylor, Robin ; Cahn-Weiner, Deborah ; Stoessl, A. Jon ; Olanow, C. Warren ; Bartus, Raymond T. / Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease : an open-label, phase I trial. In: The Lancet Neurology. 2008 ; Vol. 7, No. 5. pp. 400-408.
@article{b2350dada9834538be09f631830e6bc0,
title = "Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial",
abstract = "Background: There is an urgent need for therapies that slow or reverse the progression of Parkinson's disease (PD). Neurotrophic factors can improve the function of degenerating neurons and protect against further neurodegeneration, and gene transfer might be a means to deliver effectively these factors to the brain. The aim of this study was to assess the safety, tolerability, and potential efficacy of gene delivery of the neurotrophic factor neurturin. Methods: In this phase I, open-label clinical trial, 12 patients aged 35-75 years with a diagnosis of PD for at least 5 years in accordance with the UK Brain Bank Criteria received bilateral, stereotactic, intraputaminal injections of adeno-associated virus serotype 2-neurturin (CERE-120). The first six patients received doses of 1·3×1011 vector genomes (vg)/patient, and the next six patients received 5·4×1011 vg/patient. This trial is registered with ClinicalTrials.gov, number NCT00252850. Findings: The procedure was well tolerated. Extensive safety monitoring in all patients revealed no clinically significant adverse events at 1 year. Several secondary measures of motor function showed improvement at 1 year; for example, a mean improvement in the off-medication motor subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) of 14 points (SD 8; p=0.000121 [36{\%} mean increase; p=0.000123]) and a mean increase of 2·3 h (2; 25{\%} group mean increase; p=0·0250) in on time without troublesome dyskinesia were seen. Improvements in several secondary measures were not significant, including the timed walking test in the off condition (p=0·053), the Purdue pegboard test of hand dexterity (p=0·318), the reduction in off time (p=0·105), and the activities of daily living subscore (part II) of the UPDRS (p=0·080). 18F-levodopa-uptake PET did not change after treatment with either dose of CERE-120. Interpretation: The initial data support the safety, tolerability, and potential efficacy of CERE-120 as a possible treatment for PD; however, these results must be viewed as preliminary until data from blinded, controlled clinical trials are available. Funding: Ceregene; Michael J Fox Foundation for Parkinson's Research.",
author = "Marks, {William J.} and Ostrem, {Jill L.} and Leonard Verhagen and Starr, {Philip A.} and Larson, {Paul S.} and Bakay, {Roy AE} and Robin Taylor and Deborah Cahn-Weiner and Stoessl, {A. Jon} and Olanow, {C. Warren} and Bartus, {Raymond T.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1016/S1474-4422(08)70065-6",
language = "English (US)",
volume = "7",
pages = "400--408",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "5",

}

TY - JOUR

T1 - Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease

T2 - an open-label, phase I trial

AU - Marks, William J.

AU - Ostrem, Jill L.

AU - Verhagen, Leonard

AU - Starr, Philip A.

AU - Larson, Paul S.

AU - Bakay, Roy AE

AU - Taylor, Robin

AU - Cahn-Weiner, Deborah

AU - Stoessl, A. Jon

AU - Olanow, C. Warren

AU - Bartus, Raymond T.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Background: There is an urgent need for therapies that slow or reverse the progression of Parkinson's disease (PD). Neurotrophic factors can improve the function of degenerating neurons and protect against further neurodegeneration, and gene transfer might be a means to deliver effectively these factors to the brain. The aim of this study was to assess the safety, tolerability, and potential efficacy of gene delivery of the neurotrophic factor neurturin. Methods: In this phase I, open-label clinical trial, 12 patients aged 35-75 years with a diagnosis of PD for at least 5 years in accordance with the UK Brain Bank Criteria received bilateral, stereotactic, intraputaminal injections of adeno-associated virus serotype 2-neurturin (CERE-120). The first six patients received doses of 1·3×1011 vector genomes (vg)/patient, and the next six patients received 5·4×1011 vg/patient. This trial is registered with ClinicalTrials.gov, number NCT00252850. Findings: The procedure was well tolerated. Extensive safety monitoring in all patients revealed no clinically significant adverse events at 1 year. Several secondary measures of motor function showed improvement at 1 year; for example, a mean improvement in the off-medication motor subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) of 14 points (SD 8; p=0.000121 [36% mean increase; p=0.000123]) and a mean increase of 2·3 h (2; 25% group mean increase; p=0·0250) in on time without troublesome dyskinesia were seen. Improvements in several secondary measures were not significant, including the timed walking test in the off condition (p=0·053), the Purdue pegboard test of hand dexterity (p=0·318), the reduction in off time (p=0·105), and the activities of daily living subscore (part II) of the UPDRS (p=0·080). 18F-levodopa-uptake PET did not change after treatment with either dose of CERE-120. Interpretation: The initial data support the safety, tolerability, and potential efficacy of CERE-120 as a possible treatment for PD; however, these results must be viewed as preliminary until data from blinded, controlled clinical trials are available. Funding: Ceregene; Michael J Fox Foundation for Parkinson's Research.

AB - Background: There is an urgent need for therapies that slow or reverse the progression of Parkinson's disease (PD). Neurotrophic factors can improve the function of degenerating neurons and protect against further neurodegeneration, and gene transfer might be a means to deliver effectively these factors to the brain. The aim of this study was to assess the safety, tolerability, and potential efficacy of gene delivery of the neurotrophic factor neurturin. Methods: In this phase I, open-label clinical trial, 12 patients aged 35-75 years with a diagnosis of PD for at least 5 years in accordance with the UK Brain Bank Criteria received bilateral, stereotactic, intraputaminal injections of adeno-associated virus serotype 2-neurturin (CERE-120). The first six patients received doses of 1·3×1011 vector genomes (vg)/patient, and the next six patients received 5·4×1011 vg/patient. This trial is registered with ClinicalTrials.gov, number NCT00252850. Findings: The procedure was well tolerated. Extensive safety monitoring in all patients revealed no clinically significant adverse events at 1 year. Several secondary measures of motor function showed improvement at 1 year; for example, a mean improvement in the off-medication motor subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) of 14 points (SD 8; p=0.000121 [36% mean increase; p=0.000123]) and a mean increase of 2·3 h (2; 25% group mean increase; p=0·0250) in on time without troublesome dyskinesia were seen. Improvements in several secondary measures were not significant, including the timed walking test in the off condition (p=0·053), the Purdue pegboard test of hand dexterity (p=0·318), the reduction in off time (p=0·105), and the activities of daily living subscore (part II) of the UPDRS (p=0·080). 18F-levodopa-uptake PET did not change after treatment with either dose of CERE-120. Interpretation: The initial data support the safety, tolerability, and potential efficacy of CERE-120 as a possible treatment for PD; however, these results must be viewed as preliminary until data from blinded, controlled clinical trials are available. Funding: Ceregene; Michael J Fox Foundation for Parkinson's Research.

UR - http://www.scopus.com/inward/record.url?scp=41949110690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949110690&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(08)70065-6

DO - 10.1016/S1474-4422(08)70065-6

M3 - Article

C2 - 18387850

AN - SCOPUS:41949110690

VL - 7

SP - 400

EP - 408

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 5

ER -